83 results about "Immunologic Suppression" patented technology

The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

The invention relates to an indoleamine 2,3-dioxygenase inhibitor with a structure represented by the formula (I) and a preparation method and applications thereof. The indoleamine 2,3-dioxygenase (IDO) inhibitor is the derivative of (Z)-N'-hydroxyl-N-phenyl formamidine, has an extremely high activity on inhibiting IDO, can effectively inhibit the activity of IDO, and can be used to inhibit the immunity inhibition of patients. The inhibitor can be widely used to treat or prevent cancer/tumor, viral infection, depression, neurodegenerative diseases, wounds, age related cataract, organ-graft refection, and autoimmune disease, and can be advantageously to be used as a novel immune-suppressor.

Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives:

wherein R¹ and R² are a hydrogen atom, an amino protecting group; R³ is a hydrogen atom, a hydroxy protecting group; R⁴ is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C₁-C₁₀ alkylene group, a C₁-C₁₀ alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R⁵ is an aryl group; R⁶ and R⁷ are a hydrogen atom, a group selected from substituent group a; with the proviso when R⁵ is a hydrogen atom, Y is not a single bond or a straight chain C₁-C₁₀ alkylene group.

A medical application of periplocoside A and E in preparing the immunodepress ant with high effect and low poison is disclosed.

The invention provides a transfer factor solution for livestock and poultry. Frozen pig spleens are washed clean by use of distilled water, cut into small pieces, added with distilled water free from heat source, subjected to cell disruption by use of a tissue bruiser and prepared into homogenate; the homogenate passes through a high-pressure homogenizer under the pressure of 60 kPa and then is added with a flocculating agent for flocculation; the flocculated homogenate is centrifuged at a centrifugation ambient temperature of 4 DEG C and at a speed of 7,000 r/min; precipitate is removed; supernatant is left on standby; the supernatant is filtered by use of a microporous filtering membrane 0.45 mu m in pore diameter, and then is ultrafiltered by use of a ultrafiltration membrane 5,000 Dalton in molecular weight cutoff so as to obtain a stock solution; after viruses are removed, nicotinamide is added as a stabilizer; the stock solution is subjected to aseptic filtration by use of the microporous filtering membrane; and the obtained product is added with glycerol as a heat-resisting protective agent and then is directly and separately packed. The transfer factor solution can be applied to livestock and poultry. The preparation method is characterized by directly using the pig spleen to extract the transfer factor solution so as to save manpower and materials and improve extraction efficiency. The preparation method combines a heat-resisting protection technique with transfer factors, thereby realizing the normal-temperature preservation of the transfer factors. The transfer factor solution can improve the disease-resisting capability of organisms, relieve immunologic suppression and immunologic tolerance, can play a role in emergency adjuvant treatment, and makes up for immunization blank after vaccination before antibody production.

The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.

Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.

The invention discloses an application of a traditional Chinese medicinal composition in the preparation of anti-ageing medicines. The traditional Chinese medicinal composition is a pure traditional Chinese medicinal preparation prepared through using Cuscuta chinensis Lam., wolfberry fruit, Chinese magnoliavine and the like. Tests prove that the traditional Chinese medicinal composition can improve the learning and memory capability decline and immune suppression caused by ageing, and has a certain anti-oxidation effect.

The invention discloses a mycobacterium tuberculosis surface lipolysaccharide-antistatic nucleic acid aptamer and application thereof. The aptamer is a small molecular single-stranded deoxyribonucleic acid (ssDNA) which is specific to toxic mycobacterium tuberculosis surface lipolysaccharide ManLAM (Mannosylated Lipoarabinomannan) and has tuberculosis infection resisting and cellular immunity enhancing functions, and the nucleotide sequence of the ssDNA is shown as SEQIDNo.1. The small molecular ssDNA has a novel target spot and a novel structure which are different from those of the conventional anti-tuberculosis medicament, and has the immunologic suppression function of directly enclosing the ManLAM. The aptamer is easy to prepare and has low price; the obtained ssDNA aptamer is specifically combined on the surface of toxic mycobacterium tuberculosis; and the treatment targeting is further enhanced. The problems of increasing medicament tolerance and large side effect existing in the conventional treatment of tuberculosis are solved, and the aptamer can be taken as an effective novel anti-tuberculosis medicament or a tuberculosis diagnosis reagent.

The invention belongs to the field of medicines and discloses a pharmaceutical composition of a triptolide-containing medicine and bracken and preparation and application thereof. The triptolide-containing medicine comprises triptolide, tripterygium glycosides, thunder god vine, tripterygium hypoglaucum hutch and tripterygium regelii. The pharmaceutical composition comprises the following raw materials in parts by weight: 1 part of triptolide and 100-107 parts of bracken or 1 part of tripterygium glycosides and 1-105 parts of bracken or 1 part of thunder god vine and 0.01-1000 parts of bracken or 1 part of tripterygium hypoglaucum hutch and 0.01-1000 parts of bracken or 1 part of tripterygium regelii and 0.01-1000 parts of bracken. Compared with the original medicine containing triptolide, the pharmaceutical composition has the advantages of immunological suppression, anti-inflammatory, treatment of rheumatoid arthritis, comparative antineoplastic activity and small toxicity, enhances the medication security and can be used as a medicine for immunological suppression, anti-inflammatory, rheumatoid arthritis and antitumor.

Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.

The invention relates to a traditional Chinese medicine composition for treating nausea and vomiting caused by chemotherapy, traditional Chinese medicine decoction-free granules and application and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw materials: 6-15 parts of ginger processed pinellia, 10-15parts of dried ginger, 6-15 parts of exocarpium citri grandis, 10-15 parts of white poria, 3-12 parts of rice water processed fructus aurantii, 10-15 parts of pogostemon cablin, 2-4 parts of preparedrhizoma coptidis with rhizoma zingiberis recens juice, 3-5 parts of liquor processed scutellaria baicalensis, 15-30 parts of reed rhizome, 5-12 parts of bamboo shavings, 5-9 parts of perilla leaves, 9-15 parts of codonopsis pilosula Nnannf and 2-6 parts of raw licorice roots. The traditional Chinese medicine decoction-free granules are prepared from the above-mentioned single traditional Chinese medicine formula granules by weight. The traditional Chinese medicine composition and the traditional Chinese medicine decoction-free granules are applied to preparation of drugs for treating nausea and vomiting caused by chemotherapy. The traditional Chinese medicine composition has the advantages of replenishing qi, strengthening spleen, invigorating the stomach, calming the adverse-rising energy, eliminating phlegm, regulating body immunity and inhibiting tumor growth; synergizing with chemotherapeutic drugs to achieve enhanced sensitivity, alleviating vomiting symptoms; and regulating digestive tract functions.

The invention discloses a pseudolaric acid B and the application of derivative thereof in the preparation of immunity inhibitor. Experiments prove that the pseudolaric acid B and the derivative thereof have excellent immunity inhibiting effect and lower toxicity, so that the pseudolaric acid B and the derivative thereof or pseudolaric acetate and salt of the derivative of the pseudolaric acid B can be taken as medicine for preventing or treating exclusive reaction, autoimmune disease, inflammatory disease, allergic disease and the like which are related to immunity and caused by organ or skin grafting of mammal (especially human beings).

A cyclic peptide is provided, which consists of 3-15 amino acids connected together with each other, wherein the amino acids contained by the cyclic peptide can be the common amino acids or the rare ones, the natural amino acids or the artificial ones, the conformation of any amino acid can be L-type or D-type, and the connection sequence is free among the amino acids. The preferred formula (I) consists of 8 common amino acids connected with each other through peptide linkages to form a cyclic peptide, and the present invention also relates to the method to prepare the cyclic peptide and the application thereof to preparation of immune-suppressive drugs.

The invention discloses a scheme for avoiding organ transplantation rejection. The scheme comprises the following steps of: injecting body cell-transformed ips (induced pluripotent stem) cells of an organ receiver or cloned ES (Embryonic Stem) cells into the blastula of a pig, developing in the uterus of the pig, giving birth and feeding to an age for utilizing; or directly using a homologous or heterogeneous organ; and transplanting the organ and stem cells in sequence, and gradually reducing the dosage of an immunologic suppression medicament, wherein alien cells can be eliminated gradually under the immune action of a human body and are filled by cells of the receiver till all the alien cells in the organ are replaced by the cells of the organ receiver. The scheme has the advantages of sufficient organ source, perpetual freeness from rejection after successful transplanting, and no need of taking any immunologic suppression medicament perpetually.

The invention discloses a preparing method of biphenyl cyclo-octadiene lignans and application in the tumour prevention drug, which is characterized by the following: reducing cardiovascular toxicant or liver toxicant or kidney toxicant or marrow inhibition or immune inhibition or alopecia, adopting schizandrin to lessen side-effect of tumour prevention drug effectively.

Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of novel immuno-suppressants for treating the diseases caused by hyperfunction of human immunity (e.g. the auto-immune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis and the like), and for inhibiting the graft rejection after cell or organ transplantation.

The invention discloses cyclosporine cream for treating lupus erythematosus or psoriasis, a method for manufacturing the cyclosporine cream and application thereof. The cyclosporine cream, the method and the application have the advantages that scientific compatibility of emulsifiers and oil phases is determined, accordingly, high skin transmission of cyclosporine can be guaranteed, the cyclosporine and dexamethasone acetate are jointly applied to manufacture the cream, the cream can directly act at affected parts, synergistic effects of immune inhibition and anti-inflammation pharmacological mechanisms of the cyclosporine and the dexamethasone acetate can be realized, excellent effects for treating skin symptoms of the lupus erythematosus and the psoriasis can be realized, and the cyclosporine cream is safe and effective when locally applied; the method for manufacturing the cream is simple and feasible and is easy to popularize, and the cream can be manufactured under mild conditions.

The invention discloses an IRES-mediated recombinant adenovirus vector and the recombinant adenovirus for co-expressing CTLA4Ig and CTLA4. The preparing method thereof comprises the steps: a CTLA4Ig gene, an IRES gene and a CTLA4 gene are inserted sequentially into the downstream of a giant cell virus promoter in a pAdTrack-CMV shuttle vector, a recombinant shuttle vector carrying the CTLA4Ig gene, the IRES gene and the CTLA4 gene is then obtained, and the recombinant shuttle vector is recombined in homologous with a virus backbone vector pAdeasy-1 to obtain the recombinant adenovirus vector for co-expressing the CTLA4Ig and the CTLA4; and the recombinant adenovirus expression vector transfects packaging cells (293 cells of human embryo kidney) to obtain recombinant adenovirus, and mammalian cells are infected by the recombinant adenovirus in vitro, thereby ensuring purpose cells with immunological suppression function. The recombinant adenovirus can play an important role in the medical field, especially in the organ transplanting field, thereby having extensive application prospect.

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of T cell antigen receptor beta chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating T cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the T cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the T cell antigen receptor beta chains; carrying out high-throughput sequencing on the CDRs3 of the T cell antigen receptor beta chains, and carrying out DNA analysis on the T cell antigen receptor beta chains in the experimental group and the control group. The method for treating the CDRs3 of the T cell antigen receptor beta chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to increment of short-term and long-term survival rate of renal transplant recipients after transplantation.